Abstract 5695
Background
We previously performed a multi-step genomic study in almost 100 resected SQLC patients dichotomized according to the prognosis. Among the pathways with a biological impact on SQLC oncogenesis, PI3K/mTOR-Rictor emerged as a crucial axis [Pilotto WCLC 2016]. In order to explore the potentiality of mTOR inhibition, we present a set of in vitro experiments in RICTOR-aberrant SQLC preclinical models.
Methods
Next-generation sequencing (NGS), fluorescence in situ hybridization (FISH) and Western Blot were performed in 3 SQLC cell lines (H-1703, SK-Mes-1, Calu-1) for detecting CNG/protein profile of the PI3K/mTOR-Rictor components. The activity of PI3K/mTOR pathway targeted inhibitors in the SQLC cell lines was examined in short- (72 hours) and long-term (1 week) cell viability assays.
Results
NGS analysis revealed a different amount of RICTOR CNG among SQLC cell lines. FISH confirmed that H-1703 harbors the highest number of RICTOR copies (6) followed by SK-Mes-1 (4) and Calu-1 (3.5), suggesting polysomy of the short arm of chromosome 5 as the main mechanism of RICTOR gain. Although Rictor protein levels were similar among the cell lines, p-mTOR S2448 (active form of mTOR complexes) was higher in H-1703 than SK-Mes-1 and Calu-1. PI3K/mTOR inhibition proved more effective in H-1703, with lower IC50 values in short term treatment (Table). Similar findings were confirmed in long-term assays.Table: 1879P
| Drugs | H-1703 | Calu-1 | SK-Mes-1 |
|---|---|---|---|
| IC50 (nM) | |||
| PF-05212384 (PI3K/mTOR inhibitor) | 18 | 26 | 335 |
| AZD-2014 (Dual mTORC1/C2 inhibitor) | 145 | 217 | 215 |
| Everolimus (mTORC1 inhibitor) | Unable determine IC50 | Unable determine IC50 | Unable determine IC50 |
| MK-2206 (pan-Akt inhibitor) | Unable determine IC50 | Unable determine IC50 | Unable determine IC50 |
Conclusions
Overall, the results of our study suggest the potential implication of PI3K/mTOR-Rictor pathway in SQLC oncogenesis, thus rendering it a promising target for a targeted approach. Among the mTOR components, RICTOR CNG seems to predict a higher sensitivity to PI3K/mTOR inhibition and might represent a potential biomarker to be explored as a stratification tool in clinical trials. Confirmatory RICTOR silencing experiments are currently ongoing.
Clinical trial identification
Legal entity responsible for the study
Emilio Bria.
Funding
AIRC (Associazione Italiana per la Ricerca sul Cancro).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract